目的 探討婦樂(lè)片聯(lián)合氟羅沙星治療慢性盆腔炎的臨床療效。方法 選取濟(jì)源市中醫(yī)院2016年3月-2018年3月收治的慢性盆腔炎患者114例，隨機(jī)分成對(duì)照組和治療組，每組各57例。對(duì)照組口服氟羅沙星膠囊，0.2 g/次，1次/d；治療組在對(duì)照組的基礎(chǔ)上口服婦樂(lè)片，5片/次，2次/d，兩組均連續(xù)服用3周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者包塊直徑和盆腔積液深度、血清粒細(xì)胞-巨噬細(xì)胞集落刺激因子（GM-CSF）和轉(zhuǎn)化生長(zhǎng)因子-β1（TGF-β1）水平及臨床癥狀積分。結(jié)果 治療后，對(duì)照組臨床有效率為73.68%，顯著低于治療組的92.98%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組包塊直徑、盆腔積液深度明顯減?。?i>P<0.05），且治療后治療組明顯小于對(duì)照組（P<0.05）。治療后，兩組血清GM-CSF水平明顯降低（P<0.05），血清TGF-β1水平明顯升高（P<0.05），且治療后治療組GM-CSF和TGF-β1水平明顯優(yōu)于對(duì)照組（P<0.05）。治療后，兩組患者臨床癥狀積分顯著降低（P<0.05），且治療組臨床癥狀積分明顯低于對(duì)照組（P<0.05）。結(jié)論 婦樂(lè)片聯(lián)合氟羅沙星治療慢性盆腔炎患者臨床療效確切，可顯著緩解患者臨床癥狀，且安全性較高。

Objective To investigate the effect of Fule Tablets combined with fleroxacin in treatment of chronic pelvic inflammatory disease. Methods Women (114 cases) with chronic pelvic inflammatory disease in Jiyuan Hospital of TCM from March 2016 to March 2018 were randomly divided into control and treatment groups, and each group had 57 cases. Women in the control group were po administered with Fleroxacin Capsules, 0.2 g/time, once daily, and they were continuously treated for 3 weeks in non menstrual period. Women in the treatment group were po administered with Fule Tablets on the basis of the control group, 5 tablets/time, twice daily, and they were treated for 5 weeks. After treatment, the clinical efficacy was evaluated, and the mass diameter and the pelvic effusion depth, GM-CSF, and TGF-β1 levels, the clinical symptom scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 73.68%, which was significantly lower than 92.98% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the mass diameter and the pelvic effusion depth in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly less than those in the control group (P<0.05). After treatment, serum GM-CSF levels in two groups were significantly decreased (P<0.05), but TGF-β1 levels were significantly increased (P<0.05), and the GM-CSF and TGF-β1 levels in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the clinical symptom scores in two groups were significantly decreased (P<0.05), and the scores in the treatment group were significantly lower than that in the control group (P<0.05). Conclusion Fule Tablets combined with fleroxacin in treatment of chronic pelvic inflammatory disease has significant clinical effect, which can significantly relieve the clinical symptoms with high safety.